https://doi.org/10.4081/btvb.2024.141
Commentary on “Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicenter, open-label, randomized controlled trial”
Published: 26 June 2024
Abstract Views: 944
PDF: 232
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
To address the potential risk of acute coronary syndrome, the current clinical guidelines on coronary artery diseases recommend revascularization in significant and flow-limiting lesions, but emerging data depict vulnerable atherosclerotic coronary plaques as possibly at risk of adverse cardiac events, compared to fibroatheromous or calcific plaques [...].
Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165.
DOI: https://doi.org/10.1093/eurheartj/ehy855
Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e18-114.
DOI: https://doi.org/10.1161/CIR.0000000000001060
Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2023;148:e9-119.
DOI: https://doi.org/10.1161/CIR.0000000000001195
Stone GW, Maehara A, Lansky AJ, et al. A prospective natural history study of coronary atherosclerosis. N Engl J Med 2011;364:226-35.
DOI: https://doi.org/10.1056/NEJMoa1002358
Erlinge D, Maehara A, Ben-Yehuda O, et al. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet 2021;397:985-95.
DOI: https://doi.org/10.1016/S0140-6736(21)00249-X
Gallone G, Bellettini M, Gatti M, et al. Coronary plaque characteristics associated with major adverse cardiovascular events in atherosclerotic patients and lesions: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2023;16:1584-604.
DOI: https://doi.org/10.1016/j.jcmg.2023.08.006
Park SJ, Ahn JM, Kang DY, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024;403:1753-65.
DOI: https://doi.org/10.1016/S0140-6736(24)00413-6
Kubo T, Maehara A, Mintz GS, et al. The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. J Am Coll Cardiol 2010;55:1590-7.
DOI: https://doi.org/10.1016/j.jacc.2009.07.078
Zimmermann FM, Pijls NHJ, Gould KL, Johnson NP. Stenting "vulnerable" but fractional flow reserve-negative lesions: potential statistical limitations of ongoing and future trials. JACC Cardiovasc Interv 2021;14:461-7.
DOI: https://doi.org/10.1016/j.jcin.2020.05.036
Stone GW, Maehara A, Ali ZA, et al; PROSPECT ABSORB Investigators. Percutaneous coronary intervention for vulnerable coronary atherosclerotic plaque. J Am Coll Cardiol 2020;76:2289-301.
DOI: https://doi.org/10.1016/j.jacc.2020.09.547
Mol JQ, Bom MJ, Damman P, et al. Pre-emptive OCT-guided angioplasty of vulnerable intermediate coronary lesions: results from the prematurely halted PECTUS-Trial. J Interv Cardiol 2020;2020:8821525.
DOI: https://doi.org/10.1155/2020/8821525
How to Cite
Borghese, O., & Vincenzoni, C. (2024). Commentary on “Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicenter, open-label, randomized controlled trial”. Bleeding, Thrombosis and Vascular Biology, 3(2). https://doi.org/10.4081/btvb.2024.141
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Marwa Eltemamy, Robert Namushi, Narayanamoorthi Saravanan, Importance of assessment of carotid plaques in the managementof acute ischemic stroke: floating intracarotid plaque , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Mattia Galli, C. Michael Gibson, Dominick J. Angiolillo, Factor XI inhibitors in adjunct to antiplatelet therapy: the ultimate dual-pathway inhibition? , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Francesco Cicconi, Ankle brachial index for the diagnosis of asymptomatic lower extremity peripheral arterial disease , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Rossana Corso, Andrea Coppola, Stefano Grazioli, Cristina Dedionigi, Nicolò Tandurella, Massimo Venturini, Francesco Dentali, Iatrogenic pseudoaneurysm of inferior epigastric artery: not only a surgical complication , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz, Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024): 12th ICTHIC
- Licia Iacoviello, Maria Benedetta Donati, Unveiling the “common soil” of cardiovascular disease and cancer , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
- Domenico Prisco, Irene Mattioli, Raffaele De Caterina, Alessandra Bettiol, The new era of anticoagulation: factor XI and XII inhibitors , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Anna Falanga, Hugo Ten Cate, Bianca Rocca, How to manage antithrombotic treatments in thrombocytopenic patients with cancer. Comments on the European Haematology Association guidelines , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Pier Mannuccio Mannucci, An ecological alliance against air pollution and cardiovascular disease , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Niccolò Bitto, Vincenzo La Mura, Anna Ludovica Fracanzani, Armando Tripodi, Is non-alcoholic fatty liver disease a prothrombotic risk factor? , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
You may also start an advanced similarity search for this article.
